Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Public Library of Science full text link Public Library of Science Free PMC article
Full text links

Actions

Share

.2019 Jun 6;13(6):e0007462.
doi: 10.1371/journal.pntd.0007462. eCollection 2019 Jun.

A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters

Affiliations

A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters

Neeltje van Doremalen et al. PLoS Negl Trop Dis..

Abstract

Nipah virus (NiV) is a highly pathogenic re-emerging virus that causes outbreaks in South East Asia. Currently, no approved and licensed vaccine or antivirals exist. Here, we investigated the efficacy of ChAdOx1 NiVB, a simian adenovirus-based vaccine encoding NiV glycoprotein (G) Bangladesh, in Syrian hamsters. Prime-only as well as prime-boost vaccination resulted in uniform protection against a lethal challenge with NiV Bangladesh: all animals survived challenge and we were unable to find infectious virus either in oral swabs, lung or brain tissue. Furthermore, no pathological lung damage was observed. A single-dose of ChAdOx1 NiVB also prevented disease and lethality from heterologous challenge with NiV Malaysia. While we were unable to detect infectious virus in swabs or tissue of animals challenged with the heterologous strain, a very limited amount of viral RNA could be found in lung tissue by in situ hybridization. A single dose of ChAdOx1 NiVB also provided partial protection against Hendra virus and passive transfer of antibodies elicited by ChAdOx1 NiVB vaccination partially protected Syrian hamsters against NiV Bangladesh. From these data, we conclude that ChAdOx1 NiVB is a suitable candidate for further NiV vaccine pre-clinical development.

PubMed Disclaimer

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: SCG is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. The remaining authors declare no conflict of interest.

Figures

Fig 1
Fig 1. Single-dose vaccination with ChAdOx1 NiVB protects Syrian hamsters against a lethal challenge with NiV Bangladesh.
(a) Experimental layout. P/B = prime-boost; B = bleed; V-N = ChAdOx1 NiVB vaccination; V-G = ChAdOx1 GFP injection; S = saline injection; C = challenge; N = necropsy; T = Termination experiment. (b) Neutralizing antibodies in serum were determined via virus neutralization assay on VeroE6 cells at D-73, D-45 and D-3. (c) Survival of Syrian hamsters challenged with NiV Bangladesh. Survival of vaccinated animals was significant compared to control animals (P = <0.0001). (d) Weight loss of challenged animals. (e) Shedding of infectious virus in oropharyngeal swabs collected daily from challenged animals. NiV titers were determined via endpoint titration on VeroE6 cells. (f) Infectious virus titers in lung and brain tissue collected from challenged animals at D5. NiV titers were determined via endpoint titration on VeroE6 cells.
Fig 2
Fig 2. Single-dose vaccination with ChAdOx1 NiVB protects Syrian hamsters against bronchointerstitial pneumonia caused by NiV Bangladesh challenge.
Hamsters were vaccinated with ChAdOx1 NiVB or injected with ChAdOx1 FGP or saline and challenged with NiV Bangladesh. Lung tissue was collected at D5. Tissue sections were stained with hematoxylin-eosin (left panels) or with target-specific probes for NiV RNA, which is visible as a red-brown staining (right panels). (a-b) Lung tissue obtained at D5 of animals vaccinated with a single-dose of ChAdOx1 NiVB. (c-d) Lung tissue obtained at D5 of animals vaccinated with a prime-boost regime of ChAdOx1 NiVB. (e-f) Lung tissue obtained at D5 of animals injected with a prime-boost regime of ChAdOx1 FGP. (g-h) Lung tissue obtained at D5 of animals injected with saline. Arrow = Inflammatory cells, fibrin, edema and hemorrhage centered on terminal bronchioles. 200x magnification. H&E and ISH slides were from sequential sections.
Fig 3
Fig 3. Single-dose vaccination with ChAdOx1 NiVB protects Syrian hamsters against a lethal challenge with NiV Malaysia, but not HeV.
(a) Experimental layout. B = bleed; V-N = ChAdOx1 NiVB vaccination; V-G = ChAdOx1 FGP injection; C = challenge; N = necropsy; T = Termination experiment. (b) Neutralizing antibodies in serum were determined via virus neutralization assay on VeroE6 cells at D-31 and D-3. (c) Survival of Syrian hamsters challenged with NiV Malaysia or HeV. (d) Weight loss of challenged animals. (e) Shedding of infectious virus in oropharyngeal swabs collected daily from challenged animals. Virus titers were determined via endpoint titration on VeroE6 cells. (f) Infectious virus titers in lung and brain tissue collected from challenged animals at D4 (HeV) or D5 (NiV). Virus titers were determined via endpoint titration on VeroE6 cells.
Fig 4
Fig 4. Single-dose vaccination with ChAdOx1 NiVB protects Syrian hamsters against severe bronchointerstitial pneumonia caused by NiV Malaysia challenge, but not by HeV challenge.
Hamsters were vaccinated with ChAdOx1 NiVB or injected with ChAdOx1 FGP and challenged with NiV Malaysia or HeV. Lung tissue was collected at D4 (HeV) or D5 (NiV). Tissue sections were stained with hematoxylin-eosin (left panels) or with target-specific probes for viral RNA, which is visible as a red-brown staining (right panels). (a-b) Lung tissue obtained at D5 of animals vaccinated with a single-dose of ChAdOx1 NiVB and challenged with NiV Malaysia. (c-d) Lung tissue obtained at D5 of animals injected with a single-dose of ChAdOx1 FGP and challenged with NiV Malaysia. (e-f) Lung tissue obtained at D5 of animals vaccinated with a single-dose of ChAdOx1 NiVB and challenged with HeV. (g-h) Lung tissue obtained at D5 of animals injected with a single-dose of ChAdOx1 FGP and challenged with HeV. Arrow in H&E = Inflammatory cells, fibrin, edema and hemorrhage centered on terminal bronchioles. Arrow in ISH = Positive endothelial cells lining an artery. 200x magnification. H&E and ISH slides were from sequential sections.
Fig 5
Fig 5. Treatment with ChAdOx1 NiVB elicited antibodies provides partial protection against a lethal NiV Bangladesh challenge in Syrian hamsters.
(a) Experimental layout. B = bleed; P = passive transfer; C = challenge; N = necropsy; T = Termination experiment. (b) Reciprocal titer of NiV Bangladesh G protein-specific antibodies in serum as determined via ELISA at pre-treatment and post-treatment. As a control, serum obtained from animals vaccinated via prime only (Fig 1) were taken along. (c) Survival of animals challenged with NiV Bangladesh treated with NiV or GFP antibodies. (d) Weight loss of challenged animals. (e) Shedding of infectious virus in oropharyngeal swabs collected daily from challenged animals. (f) Infectious virus titers in lung and brain tissue collected from challenged animals at D5. Virus titers were determined via endpoint titration on VeroE6 cells.
Fig 6
Fig 6. Treatment with IgG antibodies elicited by ChAdOx1 NiVB vaccination reduced pathology and viral RNA abundance in Syrian hamsters challenged with NiV Bangladesh.
Hamsters were treated with NiV or GFP antibodies and challenged with NiV Bangladesh. Lung tissue was collected at D5. Tissue sections were stained with hematoxylin-eosin (left panels) or with target-specific probes for viral RNA, which is visible as a brown staining (right panels). (a-b) Lung tissue obtained at D5 of animals treated with NiV antibodies. (c-d) Lung tissue obtained at D5 of animals treated with GFP antibodies. Arrow in H&E = Inflammatory cells, fibrin, edema and hemorrhage centered on terminal bronchioles. 200x magnification. H&E and ISH slides were from sequential sections.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288(5470):1432–5. Epub 2000/05/29. . - PubMed
    1. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg. 2011;85(5):946–51. Epub 2011/11/04. 10.4269/ajtmh.2011.10-0567 - DOI - PMC - PubMed
    1. Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, et al. Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy. Sci Rep. 2016;6:30916 Epub 2016/08/04. 10.1038/srep30916 - DOI - PMC - PubMed
    1. WHO. Nipah virus outbreaks in the WHO South-East Asia Region 2012. Available from:http://www.searo.who.int/entity/emerging_diseases/links/nipah_virus_outb.... - PubMed
    1. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis. 2007;13(7):1031–7. Epub 2008/01/25. 10.3201/eid1307.061128 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Public Library of Science full text link Public Library of Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp